LEE'S PHARM.
李氏大藥廠

Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

POSITIVE PROFIT ALERT

This announcement is made by Lee's Pharmaceutical Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that, based on the preliminary assessment of the Group's unaudited financial information currently available to the Board, the Group is expected to record an unaudited net profit attributable to the Shareholders in the range of approximately HK$85 million to HK$95 million for the six months ended 30 June 2026 (the "**Reporting Period**") as compared with approximately HK$67.2 million recorded for the six months ended 30 June 2025.

The expected improvement of the Group's interim results was mainly attributable to, among other things, (i) growth in the Group's revenue; and (ii) an improvement in the Group's overall gross profit margin, arising from a more favourable product mix weighted towards higher-margin specialty and licensed-in products and continued manufacturing efficiency gains at the Group's production sites, which together more than offset the increases in research and development expenses, selling and distribution expenses and administrative expenses (including costs associated with the Group's newly consolidated United States operations) recorded during the Reporting Period.

The Company is in the course of finalising the interim results of the Group for the six months ended 30 June 2026. The information contained herein is only a preliminary assessment by the Board based on information currently available, including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026, which have not been confirmed, reviewed or audited by the auditor of the Company, and neither constitutes a forecast of subsequent periods nor an indication of the annual financial performance of the Group for the financial year 2026. The financial information of the Group for subsequent periods will be subject to, among other things, the business performance of the Group by then.

The interim results announcement of the Company for the six months ended 30 June 2026 is expected to be published on 31 August 2026 in full compliance with the requirements under the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 26 August 2026

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company; Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie-Chin are non-executive directors of the Company; and Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.

* *For identification purpose only*